“Two additional years of results from the European Randomized Study of Screening for Prostate Cancer (ERSPC) confirm original findings that screening significantly reduces death from prostate cancer.
Published in the New England Journal of Medicine (2012; 366:981-90), the study extended the patient follow-up to an average of 11 years and found that a man who undergoes PSA testing will have his risk of dying from prostate cancer reduced by 29%.”
For the full article please click here: http://www.modernmedicine.com/modernmedicine/article/articleDetail.jsp?id=766061&cid=UROL
